|

Pivekimab Sunirine Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: Anti-CD123 ADC IMGN632, Antibody-drug Conjugate IMGN632, CD123-targeted ADC IMGN632, IMGN 632, IMGN-632 +1 more

Pipeline

Phase 1: 1Phase 2/3: 1

Top Sponsors

  • AbbVie2

Indications

  • Acute Myeloid Leukemia2
  • Cancer2

Phoenix, Arizona1 trial

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Mayo Clinic Hospital - Phoenix /ID# 282904

Phase 2/3

Palo Alto, California1 trial

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Lucile Packard Children's Hospital /ID# 276015

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.